Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Oxford Biodynamics PLC    OBD   GB00BD5H8572

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Oxford Biodynamics : Subsidiary signs exclusive Asia licence

share with twitter share with LinkedIn share with facebook
share via e-mail
05/18/2017 | 08:09am CEST

18 May 2017

Oxford BioDynamics Plc

('OBD' or the 'Company' and, together with its subsidiaries, the 'Group')

Oxford BioDynamics subsidiary signs exclusive Asia licence for EpiSwitch™

Royalty and significant potential milestone fees; further commercial validation of the EpiSwitch™ platform

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that its subsidiary, Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement (the 'Licence') with Nova Satra Diagnostics Asia Limited ('NSDA'), to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia. Specifically for Malaysia, Oxford BioDynamics has granted its consent for NSDA to grant an exclusive sub-licence to Genting Laboratory Services Sdn Bhd, a wholly owned subsidiary of Genting Berhad, to provide the proprietary breast cancer test.

NSDA is a wholly owned subsidiary of Nova Satra Dx Pte Ltd., a Singaporean company that develops and commercialises blood-based diagnostic tests to provide the early detection of cancer. Nova Satra Dx. is an associate company of Genting Berhad, a Malaysian conglomerate.

Under the terms of the agreement, the Licence exclusively grants NSDA the right to use Oxford BioDynamics' proprietary products and reagents, provided through the Company's EpiSwitch™technology platform, for breast cancer patients stratification. NSDA will be solely responsible for completing the regulatory approval process and commercialisation activities of the breast cancer test within 13 territories in Asia. In return, Oxford BioDynamics will receive an upfront licensing payment, royalties on sales of the test and fees on the achievement of certain material undisclosed milestones.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

'Our proprietary EpiSwitch™technology will be instrumental in the development of this novel blood-based test that will assist in the diagnosis of breast cancer in the Asian population. This latest EpiSwitchlicence agreement will generate royalty and milestone fees for the Company. This agreement further demonstrates the broad application potential of OBD's technology.'

'We are very pleased to be collaborating with Nova Satra Diagnostics and look forward to developing our relationship with the team further.'

Kane Black, Chief Executive Officer of Nova Satra Diagnostics Asia, commented:

'We are pleased to be working with Oxford BioDynamics in Asia on this test, the first of a suite of innovative tests we are developing for patients specifically in Asia. Breast cancer is the most prevalent cancer in females in Asia[1]and early detection is an important factor in improving treatment outcomes and survival rates.'

Kong Han Tan, President and Chief Operating Officer of Genting Berhad, added:

'We are excited to be granted exclusive distribution rights in Malaysia for the breast cancer test using Oxford BioDynamics' proprietary EpiSwitch™technology and we welcome the opportunity to work with Oxford BioDynamics for the transfer of their technology to our labs in Malaysia to enable us deliver a non-invasive blood test to assist in the diagnosis of breast cancer.'


For further details contact:

Oxford BioDynamics Plc

+44 (0)1865 518910

Christian Hoyer Millar, CEO

Katie Long, CFO

FTI Consulting

+44 (0)20 3727 1000

Financial Public Relations Advisor

Julia Phillips

Brett Pollard

Natalie Garland-Collins

Stifel Nicolaus Europe Limited

+44 (0)20 7710 7600

Nominated Advisor and Broker

David Arch

Jonathan Senior

Peter Lees

Ben Maddison

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ('Oxford BioDynamics') is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker 'OBD'. For more information please visit www.oxfordbiodynamics.com.

About Nova Satra Dx Pte Ltd.

Singapore based Nova Satra Dx Pte Ltd. is a Molecular Diagnostics company committed to improving lives through the research, development and commercialization of blood based diagnostic tests that provide the early highly accurate detection of cancer. Widely recognized as the future of cancer diagnostics, Doctors are using molecular testing to diagnose and treat diseases more accurately and at an earlier stage than ever before.

The company is currently developing a pipeline of molecular diagnostic tests across a range of cancer indications. Our lead test, is a novel non-invasive diagnostic test for breast cancer.

For more information please visit: www.novasatra.com

Contact email: [email protected]

Oxford Biodynamics plc published this content on 18 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 May 2017 06:08:26 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22OXFORD BIODYNAMICS : Interim Results for the Period Ended 31 March 2018
04/17OXFORD BIODYNAMICS : Notice of Interim Results
04/04OXFORD BIODYNAMICS : Extending precision medicine study
02/16OXFORD BIODYNAMICS : Announces Grant of Indian Patent
02/15OXFORD BIODYNAMICS : Publication of Annual Report and Notice of AGM
02/14OXFORD BIODYNAMICS : Grant of Indian patent for EpiSwitch platform
01/31OXFORD BIODYNAMICS : Loss Widens As It Develops Core EpiSwitch Product
01/30OXFORD BIODYNAMICS : Shore Capital appointed as NOMAD and Sole Broker
01/30OXFORD BIODYNAMICS : Final Results for the Year Ended 30 September 2017
01/03OXFORD BIODYNAMICS : Signs 2nd agreement with US biopharma company
More news
Financials ( GBP)
Sales 2018 1,24 M
EBIT 2018 -2,74 M
Net income 2018 -
Finance 2018 8,00 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 144x
EV / Sales 2019 38,0x
Capitalization 187 M
Duration : Period :
Oxford Biodynamics PLC Technical Analysis Chart | OBD | GB00BD5H8572 | 4-Traders
Technical analysis trends OXFORD BIODYNAMICS PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Christian Gurth Hoyer Millar Chief Executive Officer & Director
David Jeffreys Williams Non-Executive Chairman
Paul Stockdale Chief Financial Officer & Director
Alexandre Akoulitchev Director & Chief Scientific Officer
Aroul Ramadass Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%29 932
LONZA GROUP1.41%20 059